Lithium Americas Corp vs Zoetis Inc — how do they compare? Lithium Americas Corp trades at $2.36 (market cap $850.38M), while Zoetis Inc trades at $74.56 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 35.5× Lithium Americas Corp's market cap, and Zoetis Inc pays a 2.9% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Zoetis Inc for 70 Days on average.
| LAC | ZTS | |
|---|---|---|
Market Cap | $850.38M | $30.20B |
Volume | 8,804,637 | 6,175,327 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $147.53 |
52-Week Low | $2.36 | $69.09 |
Typical Hold Time | 27 Days | 70 Days |
Enterprise Value | $1.19B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.36, down 2.28% with bearish technical signals but positive analyst sentiment. The company shows negative profitability metrics with ROE at -9.56% and net income of -$122.09M for 2025, though it has beaten EPS estimates in recent quarters. Strong financing activity ($1.14B in 2025) supports Thacker Pass development, a key growth catalyst.
Investment outlook balances development potential against current losses. The consensus price target of $4.00 suggests 70% upside, but execution risks and lithium price volatility remain concerns. Construction progress at Thacker Pass could drive rerating, though the stock faces near-term pressure from negative cash flow and market skepticism.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →